Immunometabolism: A 'Hot' Switch for 'Cold' Pediatric Solid Tumors

Lin Xiao1, Harrison Yeung2, Michelle Haber1

  • 1Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales Sydney, NSW 2052, Australia; School of Women's and Children's Health, University of New South Wales Sydney, Randwick, NSW 2052, Australia.

Trends in Cancer
|June 29, 2021
PubMed

Insights

Pediatric solid tumors evade immune attack, hindering immunotherapy. Targeting tumor metabolism offers a novel strategy to enhance immunotherapy effectiveness in children with solid cancers.

Area of Science:

  • Oncology
  • Immunology
  • Metabolic pathways

Background:

  • Immunotherapies show success in adult cancers and pediatric blood cancers, but not pediatric solid tumors.
  • Pediatric solid tumors possess mechanisms to evade the immune system, limiting current immunotherapy efficacy.
  • Altered tumor metabolism is a key factor in immune evasion within pediatric solid tumors.

Purpose of the Study:

  • To review metabolic alterations in pediatric solid tumors that promote immune escape.
  • To discuss novel strategies targeting these metabolic pathways.
  • To explore the potential of combining metabolic targeting with immunotherapy for pediatric solid cancers.

Main Methods:

  • Literature review of metabolic pathways in pediatric solid tumors.
  • Analysis of current antimetabolic strategies.
  • Exploration of potential therapeutic combinations and translational challenges.

Main Results:

  • Pediatric solid tumors exhibit specific metabolic reprogramming that supports immune evasion.
  • Targeting these metabolic pathways presents a promising avenue for overcoming immunotherapy resistance.
  • Combination of antimetabolic strategies with immunotherapies could enhance treatment efficacy.

Conclusions:

  • Metabolic reprogramming in pediatric solid tumors is a critical target for improving immunotherapy outcomes.
  • Novel antimetabolic strategies hold potential for potentiating immunotherapies in pediatric solid cancers.
  • Further research and preclinical testing are needed to translate these findings into clinical applications, particularly through personalized medicine approaches.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
48